Introduction to Hematopoietic Cell Transplantation

Chapter

Abstract

Hematopoietic cell transplantation (HCT) is a widely used treatment modality for malignant and nonmalignant hematologic diseases. Both autologous and allogeneic HCT produce substantial periods of immunosuppression and predispose recipients to a variety of common and opportunistic infections. In allogeneic HCT recipients, the development of chronic graft-vs.-host disease, which can persist for years, leads to long-lasting immunocompromise. Infection is a major cause of morbidity and mortality in HCT recipients. This chapter reviews the basic principles of HCT, with a focus on the effects of transplantation on the immune system and on the process of immune reconstitution after HCT.

Keywords

Allogeneic Hematopoietic Transplantation Bone marrow transplantation Graft-vs.-host disease Hematologic malignancy 

Notes

Acknowledgments.

This work was supported in part by grants CA018105 and CA087948 from the US National Institutes of Health and by Mentored Research Scholar Grant 12-162-01-LIB from the American Cancer Society.

References

  1. 1.
    Santos GW. History of bone marrow transplantation. Clin Haematol. 1983;12(3):611–39.PubMedCrossRefGoogle Scholar
  2. 2.
    Little MT, Storb R. History of haematopoietic stem-cell transplantation. Nat Rev Cancer. 2002;2(3):231–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Ijima S, Gushima K, Imahori S, editors. Hiroshima and Nagasaki: the physical, medical, and social effects of the atomic bombings. New York: Basic Books; 1981.Google Scholar
  4. 4.
    van Bekkum S, de Vries M. Radiation chimaeras. London: Logos Press; 1967.Google Scholar
  5. 5.
    Thomas ED, Lochte Jr HL, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 1957;257(11):491–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Mathe G, Amiel JL, Schwarzenberg L, Choay J, Trolard P, Schneider M, et al. Bone marrow graft in man after conditioning by antilymphocytic serum. Br Med J. 1970;2(5702):131–6.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Barnes DW, Loutit JF. Treatment of murine leukaemia with x-rays and homologous bone marrow. II. Br J Haematol. 1957;3(3):241–52.PubMedCrossRefGoogle Scholar
  8. 8.
    Dausset J. Iso-leuko-antibodies. Acta Haematol. 1958;20(1–4):156–66.PubMedCrossRefGoogle Scholar
  9. 9.
    Epstein RB, Storb R, Ragde H, Thomas ED. Cytotoxic typing antisera for marrow grafting in littermate dogs. Transplantation. 1968;6(1):45–58.PubMedCrossRefGoogle Scholar
  10. 10.
    Holtick U, Albrecht M, Chemnitz JM, Theurich S, Skoetz N, Scheid C, et al. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst Rev. 2014;4:Cd010189.Google Scholar
  11. 11.
    Wagner Jr JE, Eapen M, Carter S, Wang Y, Schultz KR, Wall DA, et al. One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med. 2014;371(18):1685–94.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300(19):1068–73.PubMedCrossRefGoogle Scholar
  13. 13.
    van Laar JM, Farge D, Sont JK, Naraghi K, Marjanovic Z, Larghero J, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA. 2014;311(24):2490–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Mancardi GL, Sormani MP, Gualandi F, Saiz A, Carreras E, Merelli E, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology. 2015;84(10):981–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360(5):447–58.PubMedCrossRefGoogle Scholar
  16. 16.
    Karponi G, Psatha N, Lederer CW, Adair JE, Zervou F, Zogas N, et al. Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy. Blood. 2015;126(5):616–9.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Maury S, Rosenzwajg M, Redjoul R, Marcais A, Xhaard A, Cherai M, et al. Lymphodepletion followed by infusion of suicide gene-transduced donor lymphocytes to safely enhance their antitumor effect: a phase I/II study. Leukemia. 2014;28(12):2406–10.PubMedCrossRefGoogle Scholar
  18. 18.
    Barbui AM, Galli M, Dotti G, Belli N, Borleri G, Gritti G, et al. Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma. Br J Haematol. 2002;116(1):202–10.PubMedCrossRefGoogle Scholar
  19. 19.
    Bourhis JH, Bouko Y, Koscielny S, Bakkus M, Greinix H, Derigs G, et al. Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study. Haematologica. 2007;92(8):1083–90.PubMedCrossRefGoogle Scholar
  20. 20.
    Logan AC, Weissman IL, Shizuru JA. The road to purified hematopoietic stem cell transplants is paved with antibodies. Curr Opin Immunol. 2012;24(5):640–8.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371(4):339–48.PubMedCrossRefGoogle Scholar
  22. 22.
    O’Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8(7):377–86.PubMedCrossRefGoogle Scholar
  23. 23.
    Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118(2):282–8.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Rao SS, Peters SO, Crittenden RB, Stewart FM, Ramshaw HS, Quesenberry PJ. Stem cell transplantation in the normal nonmyeloablated host: relationship between cell dose, schedule, and engraftment. Exp Hematol. 1997;25(2):114–21.PubMedGoogle Scholar
  25. 25.
    Wahlstrom JT, Dvorak CC, Cowan MJ. Hematopoietic stem cell transplantation for severe combined immunodeficiency. Curr Pediatr Rep. 2015;3(1):1–10.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Pingali SR, Champlin RE. Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant. 2015;50(9):1157–67.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124(3):344–53.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Kohrt H, Lowsky R. Nonmyeloablative conditioning with total lymphoid irradiation and antithymocyte globulin: an update. Curr Opin Hematol. 2009;16(6):460–5.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Green DJ, Shadman M, Jones JC, Frayo SL, Kenoyer AL, Hylarides MD, et al. Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. Blood. 2015;125(13):2111–9.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Mawad R, Gooley TA, Rajendran JG, Fisher DR, Gopal AK, Shields AT, et al. Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome. Biol Blood Marrow Transplant. 2014;20(9):1363–8.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Matesan M, Rajendran J, Press OW, Maloney DG, Storb RF, Cassaday RD, et al. 90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic leukemia: utility of pretransplantation biodistribution. Nucl Med Commun. 2014;35(11):1132–42.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97(11):3390–400.PubMedCrossRefGoogle Scholar
  33. 33.
    Gyurkocza B, Gutman J, Nemecek ER, Bar M, Milano F, Ramakrishnan A, et al. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. Biol Blood Marrow Transplant. 2014;20(4):549–55.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Burroughs LM, Nemecek ER, Torgerson TR, Storer BE, Talano JA, Domm J, et al. Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial. Biol Blood Marrow Transplant. 2014;20(12):1996–2003.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855–64.PubMedCrossRefGoogle Scholar
  36. 36.
    Pulsipher MA, Chitphakdithai P, Logan BR, Navarro WH, Levine JE, Miller JP, et al. Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation. Blood. 2014;123(23):3655–63.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    McCredie KB, Hersh EM, Freireich EJ. Cells capable of colony formation in the peripheral blood of man. Science. 1971;171(3968):293–4.PubMedCrossRefGoogle Scholar
  38. 38.
    Remberger M, Torlen J, Ringden O, Engstrom M, Watz E, Uhlin M, et al. Effect of total nucleated and CD34(+) cell dose on outcome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21(5):889–93.PubMedCrossRefGoogle Scholar
  39. 39.
    Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med. 2010;16(2):232–6.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012;367(24):2305–15.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Weissinger F, Sandmaier BM, Maloney DG, Bensinger WI, Gooley T, Storb R. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood. 2001;98(13):3584–8.PubMedCrossRefGoogle Scholar
  42. 42.
    Petersen FB, Buckner CD, Clift RA, Nelson N, Counts GW, Meyers JD, et al. Infectious complications in patients undergoing marrow transplantation: a prospective randomized study of the additional effect of decontamination and laminar air flow isolation among patients receiving prophylactic systemic antibiotics. Scand J Infect Dis. 1987;19(5):559–67.PubMedCrossRefGoogle Scholar
  43. 43.
    Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D, et al. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood. 2014;124(8):1372–7.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Socie G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood. 2011;117(23):6375–82.PubMedCrossRefGoogle Scholar
  45. 45.
    Bachanova V, Brunstein CG, Burns LJ, Miller JS, Luo X, Defor T, et al. Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma. Bone Marrow Transplant. 2009;43(3):237–44.PubMedCrossRefGoogle Scholar
  46. 46.
    Meijer E, Dekker AW, Lokhorst HM, Petersen EJ, Nieuwenhuis HK, Verdonck LF. Low incidence of infectious complications after nonmyeloablative compared with myeloablative allogeneic stem cell transplantation. Transpl Infect Dis. 2004;6(4):171–8.PubMedCrossRefGoogle Scholar
  47. 47.
    Pical-Izard C, Crocchiolo R, Granjeaud S, Kochbati E, Just-Landi S, Chabannon C, et al. Reconstitution of natural killer cells in HLA-matched HSCT after reduced-intensity conditioning: impact on clinical outcome. Biol Blood Marrow Transplant. 2015;21(3):429–39.PubMedCrossRefGoogle Scholar
  48. 48.
    Schulenburg A, Fischer M, Kalhs P, Mitterbauer M, Rabitsch W, Greinix HT, et al. Immune recovery after conventional and non-myeloablative allogeneic stem cell transplantation. Leuk Lymphoma. 2005;46(12):1755–60.PubMedCrossRefGoogle Scholar
  49. 49.
    Sanchez-Guijo FM, Sanchez-Abarca LI, Bueno C, Villaron E, Lopez-Holgado N, Vazquez L, et al. Long-term immune recovery of patients undergoing allogeneic stem cell transplantation: a comparison with their respective sibling donors. Biol Blood Marrow Transplant. 2005;11(5):354–61.PubMedCrossRefGoogle Scholar
  50. 50.
    Storek J, Ferrara S, Ku N, Giorgi JV, Champlin RE, Saxon A. B cell reconstitution after human bone marrow transplantation: recapitulation of ontogeny? Bone Marrow Transplant. 1993;12(4):387–98.PubMedGoogle Scholar
  51. 51.
    Ottinger HD, Beelen DW, Scheulen B, Schaefer UW, Grosse-Wilde H. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood. 1996;88(7):2775–9.PubMedGoogle Scholar
  52. 52.
    Stiehm ER, Roberts RL, Hanley-Lopez J, Wakim ME, Pallavicini MG, Cowan MJ, et al. Bone marrow transplantation in severe combined immunodeficiency from a sibling who had received a paternal bone marrow transplant. N Engl J Med. 1996;335(24):1811–4.PubMedCrossRefGoogle Scholar
  53. 53.
    Maury S, Mary JY, Rabian C, Schwarzinger M, Toubert A, Scieux C, et al. Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients. Br J Haematol. 2001;115(3):630–41.PubMedCrossRefGoogle Scholar
  54. 54.
    Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, et al. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood. 2012;119(26):6373–8.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Arai S, Sahaf B, Narasimhan B, Chen GL, Jones CD, Lowsky R, et al. Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood. 2012;119(25):6145–54.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Sarantopoulos S, Ritz J. Aberrant B-cell homeostasis in chronic GVHD. Blood. 2015;125(11):1703–7.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Jacobson CA, Sun L, Kim HT, McDonough SM, Reynolds CG, Schowalter M, et al. Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20(5):668–75.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Cutler C, Kim HT, Bindra B, Sarantopoulos S, Ho VT, Chen YB, et al. Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood. 2013;122(8):1510–7.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Peggs KS. Reconstitution of adaptive and innate immunity following allogeneic hematopoietic stem cell transplantation in humans. Cytotherapy. 2006;8(5):427–36.PubMedCrossRefGoogle Scholar
  60. 60.
    Williams KM, Gress RE. Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantation. Best Pract Res Clin Haematol. 2008;21(3):579–96.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Castermans E, Hannon M, Dutrieux J, Humblet-Baron S, Seidel L, Cheynier R, et al. Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60 years of age. Haematologica. 2011;96(2):298–306.PubMedCrossRefGoogle Scholar
  62. 62.
    Castermans E, Baron F, Willems E, Schaaf-Lafontaine N, Meuris N, Gothot A, et al. Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning. Haematologica. 2008;93(2):240–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333(16):1038–44.PubMedCrossRefGoogle Scholar
  64. 64.
    Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 1992;257(5067):238–41.PubMedCrossRefGoogle Scholar
  65. 65.
    Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99(11):3916–22.PubMedCrossRefGoogle Scholar
  66. 66.
    Odendahl M, Grigoleit GU, Bonig H, Neuenhahn M, Albrecht J, Anderl F, et al. Clinical-scale isolation of ‘minimally manipulated’ cytomegalovirus-specific donor lymphocytes for the treatment of refractory cytomegalovirus disease. Cytotherapy. 2014;16(9):1245–56.PubMedCrossRefGoogle Scholar
  67. 67.
    Tischer S, Priesner C, Heuft HG, Goudeva L, Mende W, Barthold M, et al. Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells. J Transl Med. 2014;12(1):336.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Theil A, Tuve S, Oelschlagel U, Maiwald A, Dohler D, Ossmann D, et al. Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease. Cytotherapy. 2015;17(4):473–86.PubMedCrossRefGoogle Scholar
  69. 69.
    Winston DJ, Territo MC, Ho WG, Miller MJ, Gale RP, Golde DW. Alveolar macrophage dysfunction in human bone marrow transplant recipients. Am J Med. 1982;73(6):859–66.PubMedCrossRefGoogle Scholar
  70. 70.
    Talarn C, Urbano-Ispizua A, Martino R, Perez-Simon JA, Batlle M, Herrera C, et al. Kinetics of recovery of dendritic cell subsets after reduced-intensity conditioning allogeneic stem cell transplantation and clinical outcome. Haematologica. 2007;92(12):1655–63.PubMedCrossRefGoogle Scholar
  71. 71.
    Mohty M, Blaise D, Faucher C, Bardou VJ, Gastaut JA, Viens P, et al. Impact of plasmacytoid dendritic cells on outcome after reduced-intensity conditioning allogeneic stem cell transplantation. Leukemia. 2005;19(1):1–6.PubMedGoogle Scholar
  72. 72.
    Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL, et al. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood. 2007;109(11):5058–61.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Dunbar EM, Buzzeo MP, Levine JB, Schold JD, Meier-Kriesche HU, Reddy V. The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease. Haematologica. 2008;93(12):1852–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Davis ZB, Cooley SA, Cichocki F, Felices M, Wangen R, Luo X, et al. Adaptive natural killer cell and killer cell immunoglobulin-like receptor-expressing T cell responses are induced by cytomegalovirus and are associated with protection against cytomegalovirus reactivation after allogeneic donor hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(9):1653–62.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Horowitz A, Guethlein LA, Nemat-Gorgani N, Norman PJ, Cooley S, Miller JS, et al. Regulation of adaptive NK cells and CD8 T cells by HLA-C correlates with allogeneic hematopoietic cell transplantation and with cytomegalovirus reactivation. J Immunol. 2015;195(9):4524–36.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Gimenez E, Solano C, Amat P, de la Camara R, Nieto J, Lopez J, et al. Enumeration of NKG2C+ natural killer cells early following allogeneic stem cell transplant recipients does not allow prediction of the occurrence of cytomegalovirus DNAemia. J Med Virol. 2015;87(9):1601–7.PubMedCrossRefGoogle Scholar
  77. 77.
    Munoz-Cobo B, Gimenez E, Solano C, de la Camara R, Nieto J, Lopez J, et al. An evaluation of the role of NKG2C+ natural killer cells in protection from cytomegalovirus DNAemia early following allogeneic stem cell transplantation. J Med Virol. 2014;86(5):806–11.PubMedCrossRefGoogle Scholar
  78. 78.
    Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214–9.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945–56.PubMedCrossRefGoogle Scholar
  80. 80.
    Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015;21(2):266–74.PubMedCrossRefGoogle Scholar
  81. 81.
    Stewart BL, Storer B, Storek J, Deeg HJ, Storb R, Hansen JA, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004;104(12):3501–6.PubMedCrossRefGoogle Scholar
  82. 82.
    Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373(9674):1550–61.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285(5426):412–5.PubMedCrossRefGoogle Scholar
  84. 84.
    Fowler DH, Foley J, Whit-Shan Hou J, Odom J, Castro K, Steinberg SM, et al. Clinical “cytokine storm” as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor alpha with severe gut graft-versus-host disease. Clin Gastroenterol Hepatol. 2004;2(3):237–45.PubMedCrossRefGoogle Scholar
  85. 85.
    Mohty M, Gaugler B. Inflammatory cytokines and dendritic cells in acute graft-versus-host disease after allogeneic stem cell transplantation. Cytokine Growth Factor Rev. 2008;19(1):53–63.PubMedCrossRefGoogle Scholar
  86. 86.
    Korngold R, Marini JC, de Baca ME, Murphy GF, Giles-Komar J. Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biol Blood Marrow Transplant. 2003;9(5):292–303.PubMedCrossRefGoogle Scholar
  87. 87.
    Patriarca F, Sperotto A, Damiani D, Morreale G, Bonifazi F, Olivieri A, et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica. 2004;89(11):1352–9.PubMedGoogle Scholar
  88. 88.
    Hamadani M, Hofmeister CC, Jansak B, Phillips G, Elder P, Blum W, et al. Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. Biol Blood Marrow Transplant. 2008;14(7):783–9.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Malard F, Bossard C, Brissot E, Chevallier P, Guillaume T, Delaunay J, et al. Increased Th17/Treg ratio in chronic liver GVHD. Bone Marrow Transplant. 2014;49(4):539–44.PubMedCrossRefGoogle Scholar
  90. 90.
    Reinhardt K, Foell D, Vogl T, Mezger M, Wittkowski H, Fend F, et al. Monocyte-induced development of Th17 cells and the release of S100 proteins are involved in the pathogenesis of graft-versus-host disease. J Immunol. 2014;193(7):3355–65.PubMedCrossRefGoogle Scholar
  91. 91.
    Uryu H, Hashimoto D, Kato K, Hayase E, Matsuoka S, Ogasawara R, et al. alpha-Mannan induces Th17-mediated pulmonary graft-versus-host disease in mice. Blood. 2015;125(19):3014–23.PubMedCrossRefGoogle Scholar
  92. 92.
    Das H, Imoto S, Murayama T, Kajimoto K, Sugimoto T, Isobe T, et al. Levels of soluble FasL and FasL gene expression during the development of graft-versus-host disease in DLT-treated patients. Br J Haematol. 1999;104(4):795–800.PubMedCrossRefGoogle Scholar
  93. 93.
    Maeda Y, Levy RB, Reddy P, Liu C, Clouthier SG, Teshima T, et al. Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease. Blood. 2005;105(5):2023–7.PubMedCrossRefGoogle Scholar
  94. 94.
    Miura Y, Thoburn CJ, Bright EC, Hess AD. Cytolytic effector mechanisms and gene expression in autologous graft-versus-host disease: distinct roles of perforin and Fas ligand. Biol Blood Marrow Transplant. 2004;10(3):156–70.PubMedCrossRefGoogle Scholar
  95. 95.
    Reddy P, Teshima T, Hildebrandt G, Duffner U, Maeda Y, Cooke KR, et al. Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation. Blood. 2002;100(9):3429–31.PubMedCrossRefGoogle Scholar
  96. 96.
    Marks L, Altman NH, Podack ER, Levy RB. Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients. Transplantation. 2004;77(6):804–12.PubMedCrossRefGoogle Scholar
  97. 97.
    Morris ES, MacDonald KP, Hill GR. Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL? Blood. 2006;107(9):3430–5.PubMedCrossRefGoogle Scholar
  98. 98.
    Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487–96.PubMedCrossRefGoogle Scholar
  99. 99.
    Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001;344(3):175–81.PubMedCrossRefGoogle Scholar
  100. 100.
    Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet. 2000;355(9211):1231–7.PubMedCrossRefGoogle Scholar
  101. 101.
    Daikeler T, Tyndall A. Autoimmunity following haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol. 2007;20(2):349–60.PubMedCrossRefGoogle Scholar
  102. 102.
    van den Brink MR, Moore E, Ferrara JL, Burakoff SJ. Graft-versus-host-disease-associated thymic damage results in the appearance of T cell clones with anti-host reactivity. Transplantation. 2000;69(3):446–9.PubMedCrossRefGoogle Scholar
  103. 103.
    Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005;105(7):2973–8.PubMedCrossRefGoogle Scholar
  104. 104.
    Stasi R, Cooper N, Del Poeta G, Stipa E, Laura Evangelista M, Abruzzese E, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood. 2008;112(4):1147–50.PubMedCrossRefGoogle Scholar
  105. 105.
    Stasi R, Del Poeta G, Stipa E, Evangelista ML, Trawinska MM, Cooper N, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007;110(8):2924–30.PubMedCrossRefGoogle Scholar
  106. 106.
    Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med. 1993;329(17):1225–30.PubMedCrossRefGoogle Scholar
  107. 107.
    Atkinson K, Biggs J, Concannon A, Dodds A, Young S, Wilson F, et al. A prospective randomised trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for haematological malignancy. Aust N Z J Med. 1991;21(6):850–6.PubMedCrossRefGoogle Scholar
  108. 108.
    Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96(6):2062–8.PubMedGoogle Scholar
  109. 109.
    Yanada M, Emi N, Naoe T, Sakamaki H, Takahashi S, Hirabayashi N, et al. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. Bone Marrow Transplant. 2004;34(4):331–7.PubMedCrossRefGoogle Scholar
  110. 110.
    Martin PJ, Hansen JA, Torok-Storb B, Durnam D, Przepiorka D, O’Quigley J, et al. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant. 1988;3(5):445–56.PubMedGoogle Scholar
  111. 111.
    Hartwig UF, Winkelmann N, Wehler T, Kreiter S, Schneider PM, Meyer RG, et al. Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality. Ann Hematol. 2005;84(5):331–8.PubMedCrossRefGoogle Scholar
  112. 112.
    Bredeson CN, Zhang MJ, Agovi MA, Bacigalupo A, Bahlis NJ, Ballen K, et al. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(9):993–1003.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Deeg HJ, Storer BE, Boeckh M, Martin PJ, McCune JS, Myerson D, et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant. 2006;12(5):573–84.PubMedCrossRefGoogle Scholar
  114. 114.
    Soiffer RJ, Alyea EP, Hochberg E, Wu C, Canning C, Parikh B, et al. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant. 2002;8(11):625–32.PubMedCrossRefGoogle Scholar
  115. 115.
    Meyer RG, Britten CM, Wehler D, Bender K, Hess G, Konur A, et al. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood. 2007;109(1):374–82.PubMedCrossRefGoogle Scholar
  116. 116.
    Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, et al. Consensus conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17(1):1–17.PubMedCrossRefGoogle Scholar
  117. 117.
    Olsson RF, Logan BR, Chaudhury S, Zhu X, Akpek G, Bolwell BJ, et al. Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies. Leukemia. 2015;29(8):1754–62.PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Gyurkocza B, Cao TM, Storb RF, Lange T, Leisenring W, Franke GN, et al. Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts. Biol Blood Marrow Transplant. 2009;15(10):1314–22.PubMedPubMedCentralCrossRefGoogle Scholar
  119. 119.
    Fraser CJ, Bhatia S, Ness K, Carter A, Francisco L, Arora M, et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood. 2006;108(8):2867–73.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Taur Y, Jenq RR, Perales MA, Littmann ER, Morjaria S, Ling L, et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood. 2014;124(7):1174–82.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Jenq RR, Taur Y, Devlin SM, Ponce DM, Goldberg JD, Ahr KF, et al. Intestinal blautia is associated with reduced death from graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21(8):1373–83.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Manzo VE, Bhatt AS. The human microbiome in hematopoiesis and hematologic disorders. Blood. 2015;126(3):311–8.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Division of Blood and Marrow TransplantationStanford UniversityStanfordUSA
  2. 2.Clinical Research DivisionFred Hutchinson Cancer Research Center, University of WashingtonSeattleUSA

Personalised recommendations